Skip to main content
Equibles

MDWD · MediWound Ltd.

Track MDWD — free

Use MDWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.90 -0.07 (-0.54%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$185.63M
Shares
14.39M
Volume · Nov 13 190.28K Avg daily vol (3M) 116.67K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.90 Open$13.00 Day$12.77–13.23 52W close$11.85–19.37 Avg vol 30d138K Short int1.8M · 12.4% of shares · 14.7d Short vol70% Last earningsNov 12, 2026 DataJan 2020–Nov 2026

Up next

Next earnings call
Mar 4, 2027 Est · unconfirmed · in 16 wks
Q2 2026 earnings call transcript
call held Aug 13, 2026

Latest documents

2026
Nov 12
Current report 6-K
VALUE trial advances despite wider third-quarter losses

MediWound reported third-quarter revenue of $3.6 million and a net loss of $6.0 million. The EscharEx Phase III VALUE trial remains on track to complete enrollment by the end of the first quarter of 2027, with no safety concerns identified.

4 source passages
Revenue was $3.6 million, compared with $5.4 million in the third quarter of 2025, primarily attributable to lower revenue from development services related to the U.S. government. Net loss was $6.0 million, or $0.46 per share, compared with $2.7 million, or $0.24 per share, primarily reflecting lower non-cash financial income from the revaluation of warrants. The pre-specified interim sample size reassessment and completion of enrollment remain on track for the end of the first quarter of 2027. The independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the VALUE trial and identified no safety concerns. The DSMB recommended that the VALUE trial continue as planned, without modification. Open the document at this passage
Nov 5
Current report 6-K
Share offering expected to yield $17.25 million

MediWound Ltd. agreed to sell 1,200,000 shares at $12.50 each; its underwriter exercised the option in full for 180,000 additional shares. The offering is expected to close on or about November 5, 2026, yielding approximately $17.25 million before expenses.

Read from the first part of this long document
4 source passages
On November 3, 2026, MediWound Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (the “Underwriter”), relating to the issuance and sale (the “Offering”) by the Company of 1,200,000 ordinary shares, par value NIS 0.07 per share, of the Company (the “Ordinary Shares”), at a public offering price of $12.50 per Ordinary Share. On November 4, 2026, the Underwriter exercised in full its option to purchase 180,000 additional Ordinary Shares (the “Option Shares”). The Offering is expected to close on or about November 5, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the Offering, including the Option Shares, are expected to be approximately $17.25 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$10.01M
Trailing 12 months
Net income (TTM)
−$23.51M
Trailing 12 months
Revenue growth YoY
-34.2%
Year over year
Operating margin
-337.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-17.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$25.62M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.1%
Year over year · more shares
Price change (1Y)
-29.8%
Trailing year
Short interest
12.4%
Latest settlement · 14.7 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲1912.2% $20.75M $12.72M '19 Q2 ▼80.6% $4.03M −$3.10M '20 Q2 ▲50.4% $6.06M −$3.19M '21 Q2 ▼22.9% $4.67M −$4.35M '22 Q2 ▲2.2% $4.77M $916,000 '23 Q2 ▲6.1% $5.06M −$6.30M '24 Q2 ▲12.7% $5.71M −$13.32M '25 Q2 LATEST ▼45.8% $3.09M −$7.39M '26 Q2

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −2%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 14%
near low
Momentum
relative strength
Weak
1-month return +9%
trailing
6-month return −23%
trailing
YTD return −30%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow Accumulating
67 of 78 funds reported for Sep 30 · net +184.0K sh shares · +12 new
Insider flow Distributing
Net -$75.4K over 90 days · 67% sells
Short interest Rising
12.44% of shares out · ▲ +2.3% MoM · 14.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
78 holders — near 3-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
High
Volatility 43%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 27, 2026
Full year 2026 revenue · full year 2026 Maintained $24M – $26M
Mar 5, 2026 $24M – $26M changed to May 27, 2026 $24M – $26M
Previous outlook earlier release · from the Earnings Call filed Mar 5, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · 2027 $32M – $35M
Revenue · 2028 $50M – $55M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−2% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow Accumulating
67 of 78 funds reported for Sep 30 · net +184.0K sh shares · +12 new
Insider flow Distributing
Net -$75.4K over 90 days · 67% sells
Short interest Rising
12.44% of shares out · ▲ +2.3% MoM · 14.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
78 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12 Now $13 · 14% Range high $19
vs 200-day avg -14% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MDWD
MediWound Ltd.
this stock
$185.63M -30.1% — — 12.4%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
87
% held
41.9%
Reported
67 of 78
Top holder
INVESTOR AB
Held Float
View
Held by Funds
Fund positions
17
View
Short & Settlement
Short Interest Rising
Shares short
1.8M
Days to cover
14.7d
Change
+40.7K sh
View
Short Volume
Short vol %
70%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
5.7K
Value
$69.1K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
39.0%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$75.4K
Buyers / Sellers
1 / 2
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 12, 2026
This year
12

MediWound reported third-quarter revenue of $3.6 million and a net loss of $6.0 million. The EscharEx Phase III VALUE trial remains on track to complete enrollment by the end of the first quarter of 2027, with no safety concerns identified.

View
Proposed Sales
Value
$50.3K
Shares
4.0K
Filed
Aug 28, 2026
View
Exempt Offerings
Offering
$17.2M
Filed
Oct 6, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Jan 11, 2027
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
MediWound Announces $15 Million B…
Published
Nov 3, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
MDWD -9.5% +8.9% -22.7% -3.0% -30.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -12.1% +10.0% -23.2% -2.8% -40.7%
Key facts CIK 1593984 CUSIP M68830112 13F (30d) 58 filings 54 filers Visit website Investor relations